![](https://www.pymnts.com/wp-content/uploads/2021/05/shutterstock_1124671937-1-e1632392680306.jpg)
Teva Pharmaceutical Industries has agreed to pay US$1.1 million to settle antitrust claims by buyers of Shire’s ADHD drug Intuniv, who accused Shire and Teva’s predecessor Actavis of delaying the launch of a generic version of the drug through an illegal settlement.
In a motion filed Monday, May 24, in federal court in Boston, the plaintiffs asked US District Judge Allison Burroughs to approve the deal, saying it would provide “substantial relief” to a class of consumers, known as indirect purchasers because they bought Intuniv through intermediaries. Teva first disclosed the settlement in December, but did not reveal its terms.
The company previously reached a US$20 million settlement with a class of direct purchasers, like drug wholesalers and distributors, which has already received preliminary approval. If Burroughs grants both settlement final approval, Teva will exit the litigation.
“We are pleased to move this forward on behalf of the proposed class,” said plaintiffs’ lawyer Conlee Whiteley of Kanner & Whiteley.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI